Advances in Diagnosis and Treatment for Bone and Soft Tissue Sarcoma

Dear Colleagues,

Sarcoma is one of the rare cancers. Historically, cancer treatment began with surgery and evolved into radiation therapy and chemotherapy. The development of these multimodal therapies has significantly improved the outcome of cancer treatments, including sarcomas.

At present, the development of molecular-targeted therapeutic agents and immune checkpoint inhibitors is expected to further improve the treatment results for many carcinomas.

Unfortunately, sarcomas have not fully benefited from these new therapeutic agents including molecular-targeted therapies and immune checkpoint inhibitors. This is thought to be due to the social problem that the market for novel treatment development for sarcoma is very small and the development of new drugs is not progressing because the sarcoma is one of the rare cancers, and the peculiarity of the sarcoma itself, which is different from the carcinoma. Due to these problems, sarcoma treatment has not been developed for decades.

In this Special issue, I would like to mention the current status of diagnosis and treatments for sarcoma, and the possibilities of developing novel diagnosis methods and treatments in the future.

Prof. Dr. Kazutaka Kikuta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.